NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that today Novelos is presenting two scientific posters, based on collaborations with Dr. Marcela Diaz-Montero of the University of Miami Sylvester Cancer Center and with Dr. Mark Poznansky of the Massachusetts General Hospital, affiliated with Dana Farber Cancer Institute/Harvard Cancer Center, at the ongoing American Association for Cancer Research (AACR) Tumor Immunology Conference in Miami, FL. These two presentations will report findings in animal model systems that demonstrate the ability of NOV-002 to influence immune responsiveness in the context of chemotherapy-induced immune suppression and an animal tumor model. An abstract of each poster presentation will also be published in the conference proceedings. NOV-002 is the subject of an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track, and NOV-002 has demonstrated positive results in Phase 2 trials for other cancer indications.
